Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

Phase 1

Terminated

• Conditions: Glioblastoma
• Interventions: Radiation: Stereotactic Radiosurgery; Drug: Nivolumab; Drug: Valproate

• Registration Number: NCT02648633
• Lead Sponsor: University of Virginia

Brief Summary

The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.

Detailed Description

Immune checkpoint inhibitors have the potential to treat a wide range of diverse cancers. Of particular interest to researchers is the PD-1 receptor-ligand interaction, a major pathway that many cancers hijack in order to suppress immune control. Anti-PD-1 antibodies such as nivolumab show a strong potential to treat many types of cancers including glioblastoma, the most common and most lethal brain cancer.

This study will examine a means of further focusing immune response on glioblastoma by combining stereotactic "gamma knife" radiosurgery with nivolumab. The rationale behind this intervention is that the radiation therapy will enhance immune response rate by providing additional tumor antigens from dying cells. Additionally, a study from investigators at Johns Hopkins indicates that histone deacetylase (HDAC) inhibitors may boost the anti-cancer efficacy of PD-1 antibodies like nivolumab. Valproate, a class I HDAC inhibitor, will be used concurrently with nivolumab with the goal of enhancing the effects of both the nivolumab and the radiotherapy.

Study Timeline

• Study First Submitted: 2015-12-16
• Study First Submitted QC: 2016-01-06
• Study First Posted: 2016-01-07
• Study Start: 2016-05-24
• Primary Completion: 2017-02-21
• Study Completion: 2017-02-21
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-26
• Last Update Posted: 2017-05-31

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Confirmed malignant, recurrent glioblastoma or gliosarcoma
• Subject must have adequate organ function
• Subject must still be able to care for most of his or her personal needs

Exclusion Criteria

• Subject is pregnant
• Subject has extracranial metastatic or leptomeningeal disease
• Subject has an additional malignancy that is progressing or requires active treatment, exceptions being basal cell and squamous cell carcinomas of the skin, indolent prostate cancer, chronic lymphocytic leukemia, or in situ cervical cancer
• Subject has received chemotherapy, biological therapy, or had surgery 4 weeks prior to beginning the study
• Subject has had radiation therapy within 10 weeks prior to entering beginning the study
• Subject has had prior therapy with bevacizumab
• Subject has had previous treatment with carmustine wafer except when administered as first-line treatment no less than six months prior to beginning the study
• Subject requires escalating supraphysiologic doses of corticosteroids greater than 2 mg of dexamethasone or an equivalent
• Active autoimmune disease requiring systemic treatment within the past 3 months or any syndrome that requires immunosuppressive agents
• Interstitial lung disease or active, non-infectious pneumonitis
• Evidence of greater than Grade 1 CNS hemorrhage or greater than Grade 3 venous thromboembolism
• History of uncontrolled cardiac disease
• Subject unable or unwilling to have a head contrast enhanced MRI

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Nivolumab & Valproate Following G.K.	Stereotactic Radiosurgery	Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
Nivolumab & Valproate Following G.K.	Nivolumab	Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
Nivolumab & Valproate Following G.K.	Valproate	Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.

Primary Outcome Measures

Name	Time	Method
Feasibility based on number of subjects who complete 4 doses of nivolumab	At 3 months following radiosurgery	Feasibility of the radiosurgery and drug combination will be determined based on the number of subjects who complete at least 4 doses of nivolumab.
Incidence of adverse events	From the beginning of treatment until no sooner than 30 days following the last study treatment	Safety will be assessed by imaging of necrosis, incidence and severity of adverse events, changes in laboratory findings, physical examinations, vital signs, and the number of discontinuations due to adverse events.

Secondary Outcome Measures

Name	Time	Method
Clinical Response Rate	From the beginning of treatment until documented disease progression or date of death, assessed up to 48 months.	Response to therapy will be evaluated by means of RANO criteria.

Trial Locations

Locations (1)

University of Virginia; 🇺🇸 Charlottesville, Virginia, United States